株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

抗感染症薬の世界市場(抗真菌薬、抗菌薬、抗ウイルス薬)

World Market for Anti-Infectives: Antifungals, Antibacterials and Antivirals (Treatments for HIV, HBV, HCV, Urinary Tract, Respiratory, Candidiasis and Other Infections)

発行 Kalorama Information 商品コード 230302
出版日 ページ情報 英文 220 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
抗感染症薬の世界市場(抗真菌薬、抗菌薬、抗ウイルス薬) World Market for Anti-Infectives: Antifungals, Antibacterials and Antivirals (Treatments for HIV, HBV, HCV, Urinary Tract, Respiratory, Candidiasis and Other Infections)
出版日: 2012年02月01日 ページ情報: 英文 220 Pages
概要

当レポートでは、欧米を軸とする世界の抗感染症医薬品市場に注目し、市場を抗真菌薬、抗菌薬、抗ウイルス薬の3分野に分けて、各製品タイプおよび感染タイプ別に分析しながら、産業および企業発展の成否に影響する動向や課題を探るほか、現在市販されている商品、開発段階にある製品の概要および販売予測、参入企業の競争力分析など、その全体像を把握するための最新情報を集め、概略以下の構成でお届けします。

第1章 エグゼクティブサマリー

  • イントロダクション
  • 調査の範囲と方法
  • 市場の全体規模と成長性
  • 市場に影響する課題と動向
  • 主要競合企業

第2章 イントロダクションおよび産業動向

  • 概要
    • 病原体についてのイントロダクション
  • 世界の人口動態
    • 平均寿命
  • 感染と薬剤耐性
    • 薬剤耐性の原因
    • 特定人口における薬剤耐性
    • 耐性軽減策
  • HIVの動向
  • 製造業者および販売メーカーの動向
    • 提携・連合動向
    • 開発企業の動向

第3章 抗真菌薬

  • 概要
  • 真菌感染のタイプ
  • 抗真菌薬品の説明
  • 競合分析

第4章 抗菌薬

  • 概要
  • 抗菌薬品の分類
  • 市場概要
  • 市場の全体規模および予測
  • 競合分析
  • 主要製品

第5章 抗ウイルス薬

  • 概要:ウィルスについてのイントロダクション
  • 病原ウィルスの例
  • ウィルスの機能および生活史
  • 8型ウィルスに対する宿主防御
  • ウィルスの宿主細胞侵入手順と宿主の回避行動
  • HIVとAIDS
  • ウィルス感染の統計数値
  • 抗ウィルス薬品の説明
  • ヌクレオシド類似体、酵素阻害薬、DNAポリメラーゼ阻害薬
  • プロテアーゼ阻害薬
  • その他の抗ウイルス薬

第6章 市場サマリー

  • 製品セグメント別市場(抗真菌薬、抗菌薬、抗ウイルス薬)

第7章 企業プロフィール

  • イントロダクション
  • Abbott Laboratories
  • Astellas
  • AstraZeneca
  • Bayer Healthcare Pharmaceuticals(Bayer Schering Pharma)
  • Bristol-Myers Squibb
  • Cubist
  • 第一三共
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer
  • Roche

付録:企業ディレクトリー

目次
Product Code: KLI6772957

This Kalorama Information report - The World Market for Anti-Infectives - focuses on three key segments of treatment:

  • Antifungals (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)
  • Antibacterials (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others)
  • Antivirals (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals)
  • The report covers both currently marketed and late stage development products. Revenues for each segment were generated using dollar and unit sales for each product.

A novel approach in this report is that it provides revenue by product type but also the ‘market’ for treatments by type of infection, enabling marketers to research the best markets where a variety of products may be implemented.

The report includes statistical information for infections by type worldwide, with special emphasis on the U.S. and Europe. The market segments provide an overview, description of products on the market, description of products in development, market estimates and forecasts, and competitive analysis of leading providers.

The area of anti-infectives represents an exciting frontier for development of potential life-saving products. However, there are a number of issues and trends that have a direct influence on this market and manufacturers' ability to successfully operate in the market.

The issues and trends affecting this market include:

  • Drug Resistance
  • HIV Trends, Cost, and Access to Drug Therapy
  • Other Immunocompromised Population Issues
  • Alliances and Partnerships
  • New Developments
  • Rx-to-OTC Switches

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals focused on the anti-infective industry. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers' level. The base year for data was 2011. Historical data was provided for the years 2007 through 2010, with forecast data provided for 2012 through 2015. Compound annual growth rates (CAGRs) are provided for the 2007-2011, 2011-2015 and 2007-2015 periods for each industry segment covered. Competitive analysis is provided for the years 2007 through 2011 with a special focus on 2011. The forecasted market analysis for 2011-2015 was based on probability of approval and sales of products in late stage development, future trends in current product demand, generic penetration, product marketing, and relevant demographic trends.

Companies profiled in this report include:

  • Abbott Laboratories
  • Astellas
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • Cubist
  • Daiichi Sankyo
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer
  • Roche

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Introduction
  • Scope and Methodology
  • Total Size and Growth of the Market
  • Issues and Trends Affecting Market
  • Leading Competitors

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

  • Overview
    • Introduction to Pathogens
  • Demographics of the World
    • Life Expectancy
  • Infections and Drug Resistance
    • Causes of Drug Resistance
    • Drug Resistance in Select Populations
    • Measures for Reducing Resistance
  • HIV Trends
  • Manufacturer and Marketer Trends
    • Trends in Partnerships and Alliances
    • Developers Trends
    • Aradigm
    • ARD-3100
    • Phase II
    • Cystic fibrosis
    • ARD-3150
    • Phase II
    • Bronchiectasis
    • ARD-1100
    • Preclinical
    • Inhalation anthrax
    • Trends in Rx-to-OTC Switches

CHAPTER THREE: ANTIFUNGAL DRUGS

  • Overview
  • Types of Fungal Infections
    • Superficial
    • Systemic
    • General Fungal Infection Statistics
    • Fungal Infection Risk
  • Description of Antifungal Products
    • Systemic Antifungals
    • Topical Antifungals
  • Market Overview
  • Total Market Size and Forecast
    • Antifungal Market by Product Type
    • Antifungal Market by Geographical Region
    • Market Analysis by Treated Condition
  • Competitive Analysis
    • Leading Products

CHAPTER FOUR: ANTIBACTERIAL DRUGS

  • Overview
    • Classification of Antibacterial Organisms
    • Antimicrobial Spectrum
    • Bacterial Resistance
    • Principles of Anti-bacterial Therapy
    • Combination Therapy and Prophylactic Use
    • Bacterial Infection Statistics
    • Bacterial Infection Risk
  • Classifications of Antibacterial Products
    • Aminoglycosides
    • Carbapenems
    • Cephalosporins
    • Macrolides
    • Penicillins
    • Quinolones
    • Sulfonamides
    • Tetracyclines
  • Market Overview
  • Total Market Size and Forecast
    • Antibacterial Market by Product Type
    • Antibacterial Market by Geographical Region
    • Market Analysis by Treated Condition
  • Competitive Analysis
  • Leading Products

CHAPTER FIVE: ANTIVIRAL DRUGS

  • Overview: Introduction to Viruses
  • Examples of Pathogenic Viruses
  • Virus Function and Life History
    • Replication in DNA Viruses
    • Replication of RNA Viruses
    • Replication in Retroviruses
  • Host Defenses Against Viruses 8
  • Viral Ploys to Invade Host Cells and Circumvent Host Responses
    • Invasion of Host Cells
    • Subversion of the Immune Response
    • Avoidance of Immune Detection and Attack by Killer Cells
  • HIV and AIDS
  • Viral Infection Statistics
  • Description of Antivirals Products
  • Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors
  • Protease Inhibitors
  • Other Antivirals
  • Market Overview
  • Total Market Size and Forecast
    • Antiviral Market by Product Type
    • Antiviral Market by Geographical Region
    • Market Analysis by Treated Condition
  • Competitive Analysis
    • Leading Products

CHAPTER SIX: MARKET SUMMARY

  • Market by Product Segment (Antifungals, Antibacterials, Antivirals)

CHAPTER SEVEN: CORPORATE PROFILES

  • Introduction
  • Abbott Laboratories
  • Astellas
  • AstraZeneca
  • Bayer Healthcare Pharmaceuticals (Bayer Schering Pharma)
  • Bristol-Myers Squibb
  • Cubist
  • Daiichi Sankyo
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer
  • Roche

APPENDIX: COMPANY DIRECTORY

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1: The Global Market for Anti-Infectives by Product Segment, 2007-2015
  • Figure 1-1: The Global Market for Anti-Infectives by Product Segment, 2011
  • Figure 1-2: World Market for Anti-Infectives Estimated Market Share of Leading Suppliers, 2011

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

  • Table 2-1: World Population by Selected Geographical Region, 2010 - 2050
  • Table 2-2: Average Life Expectancy in Years by Country 1980, 2004 and 2009
  • Figure 2-2: Average Life Expectancy in Years by Country 1980 and 2009
  • Table 2-3: Worldwide HIV/AIDS Infections
  • Table 2-4: Women Living with HIV/AIDS, by Region 2001 to 2009, Number
  • Table 2-5: Antiretroviral Access for HIV Infected Individuals in Low- and Middle-Income Countries, 2009 based on 2010 WHO Guidelines
  • Table 2-6: Antiretroviral Access for HIV Infected Individuals in Low- and Middle-Income Countries, by Selected Countries, 2009 based on 2010 WHO Guidelines
  • Table 2-7: Anti-Infective Drugs in Development by Developer
  • Table 2-8: Anti-infectives Ingredients Transferred from Rx-to-OTC Status
  • Figure 2-3: Anti-infectives Ingredients Transferred from Rx-to-OTC by Year

CHAPTER THREE: ANTIFUNGAL DRUGS

  • Table 3-1: Incidence of Infections by Type, 2010
  • Figure 3-1: Incidence of Infections by Type, 2010
  • Table 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010
  • Figure 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010
  • Table 3-3: Treatment Options for Fungal Infections , (Type, Brand, and Manufacturer)
  • Table 3-4: The World Market for Antifungal Drugs 2007-2015
  • Figure 3-3: The World Market for Antifungal Drugs 2007-2015
  • Table 3-5: Antifungal Drug Market by Type 2007-2015 , (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)
  • Figure 3-4: The World Market for Antifungal Drugs Revenues by Type 2007-2015 , (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)
  • Figure 3-5: The World Market for Antifungal Drugs Revenues by Type 2011 and 2015 , (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)
  • Table 3-6: The World Market for Antifungal Drugs Estimated Products Sales by Geographic Region 2007-2015
  • Figure 3-6: The World Market for Antifungal Drugs Estimated Product Sales by Geographic Region 2007-2015
  • Table 3-7: World Antifungal Market Estimated Products Sales by Infection Type , (Candida Infections, Seborrheic Dermatitis, Onychomycosis, Other Infections)
  • Figure 3-7: World Antifungal Market Estimated Distribution of Products Sales by Infection Type, 2011 Candida Infections, Seborrheic Dermatitis, Onychomycosis, Other Infections)
  • Table 3-8: World Market for Antifungal Drugs Estimated Revenues and Market Share of Leading Suppliers 2007-2011
  • Figure 3-8: World Market for Antifungal Drugs Estimated Revenues of Leading Suppliers, 5-year Comparison 2007-2011
  • Figure 3-9: World Market for Antifungal Drugs Estimated Market Share of Leading Suppliers, 2011
  • Table 3-9: World Market for Antifungal Drugs Estimated Sales of Select Products 2007-2011
  • Figure 3-10: World Market for Antifungal Drugs Estimated Sales of Select Products 2007-2011

CHAPTER FOUR: ANTIBACTERIAL DRUGS

  • Table 4-1: Antibiotics with Difficult Penetration
  • Table 4-2: Estimated World and U.S. Incidence of Bacterial Infections, 2010
  • Figure 4-1: Estimated World and U.S. Incidence of Bacterial Infections
  • Table 4-3: World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010
  • Figure 4-2: World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010
  • Table 4-4: Treatment Options for Bacterial Infections , (Type, Brand, and Manufacturer)
  • Table 4-5: The World Market for Antibacterial Drugs 2007-2015
  • Figure 4-3: The World Market for Antibacterial Drugs 2007-2015
  • Table 4-6: Antibacterial Drug Market by Type 2007-2015
  • Figure 4-4: The World Market for Antibacterial Drugs Revenues by Type, 2007-2015 , (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others)
  • Figure 4-5: The World Market for Antibacterial Drugs Revenues by Type 2011 and 2015 , (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others)
  • Table 4-7: The World Market for Antibacterial Drugs Estimated Products Sales by Geographic Region 2007-2015
  • Figure 4-6: The World Market for Antibacterial Drugs Estimated Product Sales by Geographic Region 2007-2015
  • Table 4-8: World Antibacterial Market Estimated Products Sales by Infection Type , (Upper and Lower Respiratory Tract Infections, Ear, Sinus Infections, Skin & Skin Structure Infections Gynecological Infections; Sexually Transmitted Infections, Urinary Tract Infections, Abdominal Infections, Other Infections)
  • Figure 4-7: World Antibacterial Market Estimated Distribution of Products Sales by Infection Type, 2011 , (Upper and Lower Respiratory Tract Infections, Ear, Sinus Infections, Skin & Skin Structure Infections Gynecological Infections; Sexually Transmitted Infections, Urinary Tract Infections, Abdominal Infections, Other Infections)
  • Table 4-9: World Market for Antibacterial Drugs Estimated Revenues and Market Share of Leading Suppliers 2007-2011
  • Figure 4-8: World Market for Antibacterial Drugs Estimated Revenues of Leading Suppliers 2007-2011
  • Figure 4-9: World Market for Antibacterial Drugs Estimated Market Share of Leading Suppliers, 2011
  • Table 4-10: World Market for Antibacterial Drugs Estimated Sales of Select Products 2007-2011

CHAPTER FIVE: ANTIVIRAL DRUGS

  • Table 5-1: Host Cell Receptors
  • Table 5-2: Estimated World and U.S. Incidence of Viral Infections, 2010
  • Figure 5-1: Estimated World and U.S. Incidence of Leading Viral Infections
  • Table 5-3: Treatment Options for Viral Infections , (Type, Brand, and Manufacturer)
  • Table 5-4: The World Market for Antiviral Drugs 2007-2015
  • Figure 5-2: The World Market for Antiviral Drugs 2007-2015
  • Table 5-5: Antiviral Drug Market by Type 2007-2015
  • Figure 5-3: The World Market for Antiviral Drugs Revenues by Type , (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals) 2007-2015
  • Figure 5-4: The World Market for Antiviral Drugs Revenues by Type , (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals) 2011 and 2015
  • Table 5-6: The World Market for Antiviral Drugs Estimated Products Sales by Geographic Region 2007-2015
  • Figure 5-5: The World Market for Antiviral Drugs Estimated Product Sales by Geographic Region 2007-2015
  • Table 5-7: World Antiviral Market Estimated Products Sales by Infection Type (HIV, Hepatitis, Other Infections, Total)
  • Figure 5-6: World Antiviral Market Estimated Distribution of Products Sales by Infection Type, 2011 (HIV, Hepatitis, Other Infections, Total)
  • Table 5-8: World Market for Antiviral Drugs Estimated Revenues and Market Share of Leading Suppliers 2006-2009
  • Figure 5-7: World Market for Antiviral Drugs Estimated Revenues of Leading Suppliers 2007-2011
  • Figure 5-8: World Market for Antiviral Drugs Estimated Market Share of Leading Suppliers, 2011
  • Table 5-9: World Market for Antiviral Drugs Estimated Sales of Top Products 2007-2011
  • Figure 5-9: World Market for Antiviral Drugs Estimated Sales of Top Products 2007-2011

CHAPTER SIX: MARKET SUMMARY

  • Table 6-1: The Global Market for Anti-Infectives by Product Segment, 2007-2015
  • Figure 6-1: The World Market for Anti-Infective Drugs 2007-2015
  • Figure 6-2: The Global Market for Anti-Infectives by Product Segment, 2011
  • Figure 6-3: The Global Market for Anti-Infectives by Product Segment, 2015
Back to Top